Head-To-Head Survey: Daxor (NASDAQ:DXR) & Nyxoah (NASDAQ:NYXH)

Daxor (NASDAQ:DXR) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility and Risk

Daxor has a beta of -0.45, suggesting that its stock price is 145% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Daxor and Nyxoah, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	0	0	N/A
Nyxoah	0	1	5	0	2.83

Nyxoah has a consensus price target of $20.20, indicating a potential upside of 96.31%. Given Nyxoah’s higher probable upside, analysts clearly believe Nyxoah is more favorable than Daxor.

Institutional and Insider Ownership

1.3% of Daxor shares are owned by institutional investors. 60.6% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Daxor and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Nyxoah	-843.49%	-42.14%	-33.55%

Valuation and Earnings

This table compares Daxor and Nyxoah’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.64)	-6.27

Daxor has higher earnings, but lower revenue than Nyxoah.

Summary

Daxor beats Nyxoah on 5 of the 9 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.